SATT Nord is proud to support Apmonia Therapeutics, a startup born out of academic research, which is now taking a major step forward with the launch of its fundraising campaign.
Specializing in the development of innovative therapies targeting the extracellular matrix, Apmonia Therapeutics is opening up a promising avenue in the fight against cancer. Its unique approach, based on public research promoted by SATT Nord, represents a real turning point for the medicine of tomorrow.
Supporting Apmonia Therapeutics means investing in a high-impact biotech company that serves the health of all.
We call on all stakeholders committed to innovation in healthcare, investors, and partners to mobilize and support this young company with strong potential in its growth trajectory.
Join an ambitious project at a pivotal stage:
✔ A groundbreaking therapeutic approach
✔ Promising and validated preclinical results
✔ Strong scientific and economic potential.
Invest from $1,000
Tax benefit for French residents: 50% of your investment is tax deductible!
Find out all the details and participate in the campaign on Capital Cell: https://capitalcell.com/en/campaign/apmonia-therapeutics/